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Expectations and RealityP2Y12 inhibitors are widely used in patients with acute coronary syndromes and in the secondary prevention of thrombotic
events in vascular diseases. Within the past few years, several pharmacological, genetic, and clinical limitations of the second-
generation thienopyridine clopidogrel have raised major concerns. High on-treatment platelet reactivity, which is common in
clopidogrel-treated patients, and its clinical implications led to the development of the more effective platelet P2Y12 inhibitors
prasugrel (a third-generation thienopyridine) and ticagrelor (a cyclopentyl-triazolo-pyrimidine). The pharmacokinetics and
pharmacodynamics of prasugrel and ticagrelor indicate that they provide more consistent, more rapid, and more potent
platelet inhibition than clopidogrel, which translates into improved ischemic outcomes. Nevertheless, higher efﬁcacy, which is
reﬂected by low on-treatment platelet reactivity, increases the risk of major bleeding events. Therefore, cardiologists might be
facing a new challenge in the future: to individualize the level of platelet inhibition in order to decrease thrombotic events
without increasing bleeding. The current review focuses on the use of platelet function testing and pharmacogenomic testing
in order to identify patients who either do not respond to or are at risk of not responding sufﬁciently to P2Y12 inhibitors.
Moreover, this paper discusses randomized trials, which so far have failed to show that tailored antiplatelet therapy improves
clinical outcome, and treatment options for patients with high on-treatment platelet reactivity. (J Am Coll Cardiol Intv
2013;6:1111–28) ª 2013 by the American College of Cardiology FoundationPlatelet Activation
Activation and aggregation of platelets play a central role
in the formation and propagation of intracoronary
thrombi. Platelet adhesion to the exposed matrix at the
site of vascular lesions is the initial step in thrombus
formation. Rupture of an atherosclerotic plaque exposes
collagen and von Willebrand factor (vWF), which binds
via its A3 domain to collagen and via its A1 domain
to platelet glycoprotein (GP)-Ib/IX receptors (Fig. 1) (1).
Collagen activates platelets directly via the GP-VI receptor
and integrin a2b1, which leads to the release of the
contents from the platelet-dense granules, which in turn
contain platelet agonists such as adenosine diphosphate
(ADP), and alpha-granules. The latter contain ﬁbrinogen,
factor V, and P-selectin. ADP binds to platelet P2Y12
and P2Y1 receptors, and ampliﬁes responses to other agonists
such as thrombin (2). Thrombin mediates its effects through
the protease-activated receptors 1 and 4, augmenting platelet
activation and aggregation. ThromboxaneA2, amajor platelet
metabolite of arachidonic acid, binds to the thromboxane
prostanoid receptor, thus amplifying platelet aggregationreceived lecture or consultant fees from AstraZeneca, Daiichi Sankyo, and Eli Lilly and
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to the GP-IIb/IIIa (aIIbb3) receptor, which leads to
ﬁbrinogen–platelet cross-linking and to the formation of
a hemostatic plug at sites of vascular injury. The local
concentration of tissue factor initiates the extrinsic clotting
of more thrombin and to the propagation of a ﬁbrin clot.P2Y12 Receptor
The P2Y12 receptor plays a crucial role in thrombus
formation and stabilization: Activation of the receptor
ampliﬁes dense granule secretion and platelet aggregation
induced not only by ADP but also by thromboxane A2
and the protease-activated receptor 1 receptor agonists.
The alpha-granule release and subsequent expression of
P-selectin on activated platelets also are ampliﬁed by the
P2Y12 activation. Stimulation of the P2Y12 receptor
sustains the activation of the GP-IIb/IIIa and GP-Ia/IIa
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Abbreviations
and Acronyms
ADP = adenosine
diphosphate
AUC = area under the curve
CADP = collagen/adenosine
diphosphate
CYP = cytochrome P450
GP = glycoprotein
HTPR = high on-treatment
platelet reactivity
MACE = major adverse
cardiac events
MEA = multiple electrode
aggregometry
OR = odds ratio
PCI = percutaneous coronary
intervention
PGE1 = prostaglandin E1
ROC = receiver-operating
characteristic
TEG = thrombelastography
VASP = vasodilator-
stimulated phosphoprotein
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1113P2Y12 Receptor Antagonism
The P2Y12 receptor is the target of several antagonists that
have proven therapeutic value for the prevention of cardio-
vascular events. Ticlopidine, clopidogrel, prasugrel, and
ticagrelor are approved oral antagonists, whereas the intra-
venous compound cangrelor and the orally active BX-667,
which both reversibly block the P2Y12 receptor, are in clinical
development (4). Ticlopidine is only infrequently prescribed
due to its unfavorable safety proﬁle, whereas clopidogrel is
the most widely used antiplatelet agent. Prasugrel and tica-
grelor represent novel P2Y12 receptor inhibitors.
Clopidogrel. Clopidogrel, a second-generation, thienopyridine-
type, irreversible inhibitor of the P2Y12 receptor, is a pro-
drug, requiring complex enteric and hepatic metabolism by
the cytochrome P450 (CYP) enzymes (Fig. 2). After
absorption, the majority of clopidogrel (up to 90%) is
metabolized by carboxyesterase-1 to an inactive carboxylic
acid derivative, SR26334. The hepatic conversion of clopi-
dogrel to its active metabolite, R-130964, is a 2-step process
via the formation of 2-oxo-clopidogrel. In these 2 steps,
CYP2C19 appears to have the most prominent role, with
lesser involvement from CYP2B6, CYP1A2, CYP3A/A5,
and CYP2C9. The maximum mean inhibition of ADP-
induced platelet aggregation of 40% to 60% is achieved
within 2 to 6 h in healthy individuals and in patients
with stable angina after administration of a loading dose of
600 mg of clopidogrel, which mirrors the extensive hepatic
metabolism of the prodrug (5).
CLOPIDOGREL RESPONSE VARIABILITY. Numerous studies
have shown that the level of platelet inhibition by clopi-
dogrel varies considerably between patients (6,7). Platelet
function measurements in clopidogrel-treated patients have
shown that, on average, 25% of patients (up to 50%, de-
pendent on the assay used) have high on-treatment platelet
reactivity (HTPR). Factors associated with clopidogrel
response variability include clinical and genetic variables
as well as drug–drug interactions (Table 1). The clinical
factors include diabetes mellitus, acute coronary syndromes,
high body mass index, renal failure, age, heart failure,
inﬂammation, and smoking (which is less frequently asso-
ciated with HTPR) (8–11). Drug–drug interactions may
also account for variability in response to clopidogrel.
Especially, CYP2C19- and CYP3A4-inhibiting drugs
(calcium channel blockers, the proton pump inhibitors
omeprazole and esomeprazole, phenprocoumon, ketocona-
zole) may reduce clopidogrel efﬁcacy (10,12–19). As clopi-
dogrel requires hepatic bioactivation, genetic polymorphisms
of CYP isoenzymes play a role in HTPR. The most impor-
tant impact comes from CYP2C19 polymorphisms (20–22).
ASSOCIATION BETWEEN RESPONSE VARIABILITY TO
CLOPIDOGREL AND CLINICAL OUTCOME. Poor response to
clopidogrel was ﬁrst described a decade ago. Since then,a huge amount of data has been generated. More than 40
studies with over 20,000 patients have demonstrated a clear
association between reduced response to clopidogrel and
adverse ischemic events (Table 2). The strongest association
was found between poor clopidogrel response and short-
term thrombotic events, particularly acute and subacute stent
thrombosis (odds ratio [OR]: 2 to 10) (Table 2) (23–29).
More than 30 studies conﬁrmed that ADP-induced platelet
aggregation is the best established marker for the prediction
of ischemic events in clopidogrel low responders or non-
responders (30–33) (Table 2). More than 20 outcome
studies have clearly demonstrated that a single measurement
of platelet function by light transmission aggregometry
(LTA) in patients undergoing elective or urgent coronary
stenting might predict adverse
events (34–37). Similar results
were obtained with the new-
generation impedance aggreg-
ometry test (multiple electrode
aggregometry [MEA], Multi-
plate analyzer, Dynabyte/Roche,
Munich, Germany) (23,25,38–42).
Further studies using the Ver-
ifyNow assay (Accumetrics, San
Diego, California) as a point-of-
care test conﬁrmed the association
between poor clopidogrel respon-
siveness and increased risk of
cardiac ischemic events during
short- and long-term follow-up
(Table 2) (34,43–45). Concor-
dantly, a ﬂow-cytometric vasodi-
lator-stimulated phosphoprotein
(VASP) phosphorylation assay
also has been reported to predict
outcome in clopidogrel nonre-
sponders (46,47).
Some recent studies postulate
that there is a threshold effect for
P2Y12 receptor blockers, indi-
cating that HTPR occurring in clopidogrel low responders
is associated with thrombotic events, whereas low on-treat-
ment platelet reactivity as demonstrated in super-responders
might correspond with bleeding events. Accordingly, several
reports have shown a clear association between an enhanced
response to clopidogrel or prasugrel and bleeding hazards
(Table 3). For a better understanding of its clinical impor-
tance, this association has to be conﬁrmed in additional trials.
Phenotyping: Test Systems Used for Assessment
of the Effect of Antiplatelet Drugs
The degree of platelet inhibition by clopidogrel can be
detected by laboratory investigation and corresponds to the
Figure 1. Receptors Involved in Platelet Activation and Aggregation and Binding Sites of Platelet Inhibitors
ADP ¼ adenosine diphosphate; COX ¼ cyclooxygenase; GP ¼ glycoprotein; TP ¼ thromboxane-prostanoid receptor 1; TXA2 ¼ thromboxane A2.
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1114phenotype of its response. The aim of platelet function
testing is to obtain the magnitude of platelet inhibition by
the respective antiplatelet drug and its relation to the risk of
ischemic and bleeding events. Different test systems are
commercially available for monitoring the effect of anti-
platelet drugs. The ideal test should be easy to perform,
rapid, highly reproducible, cost-effective, and provide
prognostic information regarding the risk of ischemic events,
but such a test does not exist at the moment. Different tests
characterize certain biological pathways of platelet activation,and each test has speciﬁc advantages and disadvantages
because no single test encompasses the complexity of platelet
biology. The magnitude of the antiplatelet effect of drugs
can be quantiﬁed by use of platelet aggregometry, ﬂow
cytometry, shear-dependent assays, platelet counting, or
other related methods such as thrombelastography.
Platelet aggregometry. Platelet aggregometry is a platelet
function test based on the stimulation of platelet–platelet
aggregation with various agonists. Two different techniques
are most widely used: optical and impedance aggregometry.
Figure 2. Metabolic Pathways of ADP Receptor Blockers
ADP ¼ adenosine diphosphate; CYP ¼ cytochrome P450.
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1115Light transmission aggregometry. LTA (optical, turbidi-
metric) is the mostly widely used platelet function test. To
detect inhibition of the P2Y12 receptor, ADP is added, and
the change in the light transmittance is then recorded. The
parameters used are the maximal aggregation and the ﬁnal
aggregation responses, expressed as percentages.
The most important advantage of optical aggregometry is
its availability and the large amount of data showing good
correlation between the results and adverse events. The
disadvantages include time-consuming centrifugation steps
with potential loss of large and dense platelets, variablereproducibility, large required sample volumes, and lengthy
processing time.
The mostly widely proposed normal value (without P2Y12
receptor blockers) of the maximal ADP-induced aggregation
response is >70% (for an ADP concentration of 20 mmol/l).
Nevertheless, the cutoff depends on ADP concentration and
use of maximal or ﬁnal aggregation, and unfortunately, there
is no consensus on the optimal ADP concentration. LTA
predicts ischemic events with a sensitivity of 60% to 79%,
a speciﬁcity of 59% to 82%, an area under the receiver-
operating characteristic (ROC) curve (AUC) of 0.73% to
Table 1. Factors Linked to Clopidogrel Response Variability
Mechanisms Ref. #
Clinical factors
Age (14,132,133)
Diabetes (9,10,119,134)
ACS (9–11)
BMI (25,133,135,136)
Reduced LVF (9,10)
Renal failure (119,137,138)
Inﬂammation (11,134,139)
Smoking (140,141)
Sex (142)
Platelet count (11,143)
Fibrinogen levels (143–145)
Underdosing (10,146)
Compliance (147)
Gene polymorphisms
CYP2C19*2 loss of function (85,87,138,148)
CYP2C19*3, *4, *5, *6, *7, *8, *9 loss of function (20–22)
CYP2C19*17 gain of function (61,98,149)
CYP2C9, gene variants (21)
CYP3A4, A5 gene variants (150–153)
ABCB1 gene variants (10,61,100)
ABCC3 gene variants (154)
ITGB3 gene variants (10)
IRS-1 gene variants (155)
Drug–drug interactions
CCB (12–15)
PPI, especially omeprazole (10,16–19)
Phenprocoumon (156)
Ketoconazole (157)
ABCB1 ¼ ATP-binding cassette sub-family B member 1; ABCC3 ¼ gene encoding canalicular
multispeciﬁc organic anion transporter 3; ACS ¼ acute coronary syndrome; BMI ¼ body mass
index; CCB ¼ calcium-channel blocker; CYP ¼ cytochrome P450; ITGB3 ¼ gene encoding
integrin beta-3; IRS ¼ insulin receptor substrate; LVF ¼ left ventricular function; PPI ¼ proton-
pump inhibitor.
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11160.85%, OR of 3 to 35 (29,30,34,48–50). Effectiveness of
LTA to predict stent thrombosis was also reported to be
good (OR: 3 to 6; AUC: 0.70, sensitivity 70%, and
speciﬁcity 68%) (Table 2) (24,26,28,29). Two studies have
shown that LTA also predicts bleeding events (Table 3)
(36,51).
Impedance aggregometry: MEA. MEA is an impedance
aggregometer used for measurement of whole-blood platelet
aggregation (Multiplate analyzer). For the detection of
inhibitory effects at the P2Y12 receptor, ADP is used as an
agonist, with or without the antagonist prostaglandin E1
(PGE1). A dilution of whole blood and 0.9% NaCl is stirred
in the test cuvettes, ADPþPGE1 or ADP alone is added,
and the increase in electrical impedance is expressed as the
AUC of the impedance tracing. The system detects the
electrical impedance change caused by adhesion and aggre-
gation of platelets on 2 independent electrode-set surfaces inthe test cuvette, expressed as arbitrary aggregation units 
minutes or as units (U) (19,52,53).
Advantages of MEA include semiautomatic, dual
measurement as an internal control, use of whole blood,
short processing time and rapid result delivery, good
reproducibility, and small required sample volume. Recently,
hirudin has been introduced as an anticoagulant, allowing
the study of platelet aggregation in a more natural envi-
ronment in which calcium and magnesium ions are present.
A good reproducibility of MEA has been reported (<6%
variability) (54). The normal value (without P2Y12 receptor
blockers) of the ADP-induced aggregation is >46 U. ADP-
induced aggregation values of >46 U and ADPþPGE1-
induced aggregation values of >48 U were most sensitive to
predict stent thrombosis (25,38–40) (Table 2). Effectiveness
of MEA to predict stent thrombosis was reported to be high
(OR: 9 to 37; ROC AUC: 0.78 to 0.92, sensitivity 70% to
90%, and speciﬁcity 84% to 100%) (23,25,38). MEA has
also been shown to predict major bleedings (ROC AUC:
0.61 to 0.74, sensitivity 72% to 77%, and speciﬁcity 62% to
66%) (Table 3) (39,40,55,56).
VerifyNow. The VerifyNow assay is a citrated whole-blood
optical detection system measuring agonist-induced activa-
tion of platelets, which bind to ﬁbrinogen-coated poly-
styrene beads. When the platelet–bead complexes fall
out of the solution, infrared light transmittance increases.
The assay uses ADP and PGE1 as agonist/antagonist
combination and reports results as P2Y12 reaction units (57).
Advantages of the VerifyNow assay include full automa-
tion, use of whole blood, good reproducibility, bedside use,
and small blood volume requirement. The most important
disadvantage is that the test kits are expensive.
The normal value (without P2Y12 receptor blockers) is
>235 P2Y12 reaction units (Table 2). However, recent
investigations have shown that with a cutoff value of >208
P2Y12 reaction units, a better detection of clinical low- or
non-responders to clopidogrel treatment is possible (58–60).
VerifyNow has been shown to predict major adverse cardiac
events (MACE) (OR: 1 to 6.5; ROC AUC: 0.56 to 0.87,
sensitivity: 60% to 80%, and speciﬁcity 63% to 92%)
(Table 2) (43,61,62). In 1 study, the VerifyNow assay pre-
dicted major bleeding events (OR: 0.94; AUC: 0.84,
sensitivity 81%, and speciﬁcity 80%) (61).
VASP phosphorylation. The VASP phosphorylation assay
(BioCytex, Marseille, France) measures the inhibition of the
P2Y12 receptor and 1 of its intracellular signaling pathways:
phosphorylation of VASP (63,64). Blood samples are incu-
bated with ADP and/or PGE1 before ﬁxation. Platelets are
permeabilized, labeled with a monoclonal antibody against
serine 239–phosphorylated VASP or its isotope, followed by
a secondary ﬂuorescein isothiocyanate–conjugated polyclonal
goat anti-mouse antibody. Mean ﬂuorescence intensity is
determined using a ﬂow cytometer. Platelet reactivity is
expressed as the platelet reactivity index (PRI).
Table 2. Studies Investigating the Association Between the Phenotype of Clopidogrel Response and Cardiac Ischemic Events
Study (Ref. #) Method:Agonist N Population Follow-Up Outcome OR/HR
Matetzky et al. (6) LTA:ADP 60 PCIþSTEMI 6 months MACE 6.00
Gurbel et al. (30) LTA:ADP 297 Elective PCI 2 years MACE 3.90
CREST (158) LTA:ADP 100 History of ST vs. no ST
PREPARE POST-STENTING (48) LTA:ADP 192 Elective PCI 6 months MACE 2.70
CLEAR PLATELETS (37) LTA:ADP 120 Elective PCI In-hospital Periprocedural MI
CLEAR PLATELETS-2 (33) LTA:ADP 200 Elective PCI In-hospital Periprocedural MI
Frere et al. (49) LTA:ADP 195 NSTE-ACSþPCI 1 month MACE 8.00
Cuisset et al. (29) LTA:ADP 598 NSTE-ACSþPCI 1 month ST 5.80
Cuisset et al. (159) LTA:ADP 106 NSTE-ACSþPCI 1 month MACE 22.40
Cuisset et al. (31) LTA:ADP 190 NSTEMIþPCI In hospital Periprocedural MI 1.80
POPULAR (34) LTA:ADP 1,049 Elective PCI 1 year MACE 2.09
Bliden et al. (50) LTA:ADP 100 Elective PCI 1 year MACE 34.60
Lev et al. (32) LTA:ADP 150 Elective PCI In-hospital Myonecrosis 1.87
Gori et al. (28) LTA:ADP 746 PCIþDES 6 months ST 3.15
Geisler et al. (24) LTA:ADP 1,019 PCI 3 months ST 2.21
Geisler et al. (9) LTA:ADP 1,092 PCI 1 month MACE 1.71
EXCELSIOR (35) LTA:ADP 802 Elective PCI 1 month MACE 6.70
Buonamici et al. (26) LTA:ADP 804 PCIþDES 6 months ST 3.08
Wang et al. (160) LTA:ADP 386 Elective PCIþDES 1 year MACE 2.44
Wenaweser et al. (161) LTA:ADP 82 History of ST vs. no ST Case/control
RECLOSE 2-ACS (36) LTA:ADP 1,789 ACSþPCI 2 years MACE 1.49
Sibbing et al. (23) MEA:ADP 1,608 Elective PCI 1 month ST 9.40
Sibbing et al. (39,40) MEA:ADP 2,533 Elective PCI 1 month ST 0.40
Eshtehardi et al. (41) MEA:ADP 219 PCI 1 month MACE
Müller-Schunk et al. (162) MEA:ADP 50 Neurointerventional stent STþTIA/stroke
Siller-Matula et al (134) MEA:ADP 403 PCI 1 year MACE 1.75
PEGASUS-PCI (38) MEA:ADP 416 PCI 1 year ST, MACE
Dineva et al. (42) MEA:ADP 603 PCI 1 month ST 24.3
Siller-Matula et al. (25) MEA:ADPþPGE1 416 PCI 6 months ST
PEGASUS-PCI (38) MEA:ADPþPGE1 416 PCI 1 year ST, MACE 36.9
Bonello et al. (68) VASP assay 144 PCI 6 months MACE
Bonello et al. (47) VASP assay 301 ACSþPCIþprasugrel 1 month MACE 23.0
Siller-Matula et al. (25) VASP assay 416 PCI 6 months ST NS
PEGASUS-PCI (38) VASP assay 416 PCI 1 year ST, MACE NS
Blindt et al. (64) VASP assay 99 PCI at high ST risk 6 months ST 1.16
Frere et al. (49) VASP assay 195 NSTE-ACSþPCI 1 month MACE 11.18
Barragan et al. (163) VASP assay 46 History of ST vs. no ST 1 month ST
Cuisset et al. (29) VASP assay 598 NSTE-ACSþPCI 1 month ST NS
WILMAA (46) VASP assay 300 PCI 6 months MACE 1.04
Price at al. (43) VerifyNow 380 PCI 6 months MACE 6.50
Campo et al. (61) VerifyNow 300 PCI 1 year MACE 1.02
Park et al. (164) VerifyNow 2,849 PCIþDES 2.2 years MACE NS
Marcucci et al. (62) VerifyNow 683 ACSþPCI 1 year MACE 2.52
POPULAR (34) VerifyNow 1,055 Elective PCI 1 year MACE 2.53
POPULAR (165) VerifyNow 422 Elective PCI 1 year MACE 2.5
Cuisset et al. (45) VerifyNow 120 Elective PCI In-hospital Periprocedural MI 4.60
ARMYDA PRO (44) VerifyNow 160 PCI 1 month MACE 6.10
POPULAR (34) Plateletworks 606 Elective PCI 1 year MACE 2.22
PREPARE POST-STENTING (48) TEG:ADP 192 Elective PCI 6 months MACE 22.60
Bliden et al. (50) TEG:ADP 100 Elective PCI 1 year MACE 26.80
POPULAR (34) PFA100:CADP 812 Elective PCI 1 year MACE NS
PEGASUS-PCI (38) PFA100:CADP 416 PCI 1 year ST, MACE NS
Continued on the next page
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Table 2. Continued
Study (Ref. #) Method:Agonist N Population Follow-Up Outcome OR/HR
Chiu et al. (78) PFA100:CADP 144 PCI 2 years MACE 5.3
Campo et al. (79) PFA100:CADP 135 STEMIþPCI 2 years MACE 4.5
Gianetti et al. (76) PFA100:CADP 175 ACS or CAD 6 months MACE 22.9
POPULAR (34) PFA100: Innovance 588 Elective PCI 1 year MACE NS
Matetzky et al. (6) CPA 60 PCIþSTEMI 6 months MACE 6.00
POPULAR (34) CPA 910 Elective PCI 1 year MACE NS
POPULAR (34) CPA:ADP 905 Elective PCI 1 year MACE NS
PEGASUS-PCI (38) CPA:ADP 416 PCI 1 year ST, MACE NS
Bliden et al. (50) TEG 100 Clopidogrel use 1 year MACE
ACS ¼ acute coronary syndrome; ADP ¼ adenosine diphosphate; CAD ¼ coronary artery disease; CADP ¼ collagen/adenosine diphosphate; CPA ¼ cone and platelet analyzer; DES ¼ drug-eluting stent(s);
HR ¼ hazard ratio; LTA ¼ light transmission aggregometry; MACE ¼ major adverse cardiac events; MEA ¼ multiple electrode aggregometry; MI ¼ myocardial infarction; NS ¼ nonsigniﬁcant; NSTE ¼ non–
ST-segment elevation; NSTEMI ¼ non–ST-segment elevation myocardial infarction; OR ¼ odds ratio; PCI ¼ percutaneous coronary intervention; PFA100 ¼ platelet function analyzer; PGE1 ¼ prostaglandin
E1; ST ¼ stent thrombosis; STEMI ¼ ST-segment elevation myocardial infarction; TEG ¼ thrombelastography; TIA ¼ transient ischemic attack; VASP ¼ vasodilator-stimulated phosphoprotein; other
abbreviations as in Table 1.
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1118An important advantage of the VASP assay is the fact
that it is the most speciﬁc assay for P2Y12 signaling, being
the only assay that is able to evaluate the extent of P2Y12
receptor inhibition without the inﬂuence of the P2Y1
receptor. Moreover, it is the only assay for determination of
P2Y12 receptor inhibition in patients on treatment with GP-
IIb/IIIa inhibitors. The disadvantages include the number of
steps and reagents (PGE1, VASP antibody), requirements of
ﬂow cytometry equipment, and the need for an experienced
technician.
The VASP assay has been shown to have high repro-
ducibility, even after repeated testing of the same sample
over 24 h; the coefﬁcient of variation for duplicate analysis
was 5% (65,66). The normal value (without P2Y12 receptor
blockers) of the platelet reactivity index is 69% to 100% (12).
Platelet reactivity index values of >42% were most sensitive
to predict ischemic events (64,67,68) (Table 2). A positive
VASP test result corresponded to an OR of 1.04 to 11.18
(49,64) to predict stent thrombosis or MACE (ROC AUC:
0.55 to 0.79) with high sensitivity (70% to 100%) (25,68),
but low speciﬁcity (25% to 37%) (Table 2) (25,38,68). The
use of a higher cutoff (60%) has been recently proposed, but
clinical studies to prove the validity of this proposal are still
lacking (69–71).
Platelet function analyzer. The PFA-100 platelet function
analyzer (Dade Behring, Marburg, Germany) measures the
time required for occlusion of the aperture by platelet plugs
(closure time) under high shear rates (5,000 to 6,000 s1).
A constant vacuum of 4,000N/m2 ismaintained in the system
that mimics the pressure of the capillary. The instrument
aspirates a blood sample under constant vacuum from the
sample reservoir through a capillary and a microscopic aper-
ture (147 mm) cut into the membrane, which leads to high
shear–induced platelet plug formation (72). For the detection
of the effects of ADP antagonists, the membrane is coated
with collagen/adenosine diphosphate (CADP) or CADP/
PGE1 (the Innovance cartridge, Dade Behring).The advantages of PFA-100 include use of whole blood,
a short processing time, evaluation of platelet adhesion, and
aggregation under high shear, which corresponds to the in
vivo process of thrombus formation. Disadvantages are the
high dependence on the level of vWF and a low sensitivity of
the test to assess the level of clopidogrel-induced platelet
inhibition (34,38,73), which make the clinical utility of the
PFA-100 CADP kit debatable.
Published data regarding reproducibility of the test are
contradictory, ranging from good to poor reproducibility
(72,74,75). The reference value for CADP closure time in
individuals not treated with P2Y12 receptor antagonists is 65
to 120 s (72). Some small studies have indicated a usefulness
of the device for prediction of MACE (OR: 3.2 to 22.9) in
clopidogrel users (76–79) (Table 2). A cutoff of 72 s has
been associated with a sensitivity of 86% and a speciﬁcity of
76% (79) to detect ischemic events.
Cone and platelet analyzer. The cone and platelet analyzer
(Impact-R,DiaMed,Cressier, Switzerland) tests whole-blood
platelet adhesion and aggregation under ﬂow conditions.
Whole blood is pre-incubated with ADP, and a shear rate of
1,800 s1 is applied (80). The adherent platelets are stained,
and the percentage of surface coverage and the average size of
the objects are determined by an image analyzer (81).
The advantages of the assay include use of whole blood
and evaluations of platelet adhesion and aggregation under
high shear rates, which correspond to the in vivo process
of thrombus formation. The disadvantages are lengthy
processing time with pre-incubation steps, requirement of
a laboratory technician, and lack of standardization.
Good reproducibility was reported for the device (<5%
variability) (82). The following normal ranges have been
proposed: surface coverage in the presence of ADP:
<4.6%, the average size in the presence of ADP of
aggregates >46 mm2 (38). The usefulness of the cone and
platelet analyzer for prediction of adverse events has been
tested only in a few studies, which overall suggested that
Table 3. Studies Investigating the Association Between the Phenotype of Clopidogrel Response and Bleeding Events
Study (Ref. #) Method:Agonist N Population Follow-Up Outcome OR/HR
Parodi et al. (36) LTA:ADP 298 PCIþprasugrel 6 months TIMI major bleeding 0.91
Chen et al. (51) LTA:ADP 45 Surgery under clopidogrel Blood transfusion
Cuisset et al. (166) VASP 597 NSTEMIþPCI 1 month TIMI bleeding non-CABG related
Mokhtar et al. (167) VASP 346 PCI In-hospital TIMI major bleeding non-CABG 0.96
Michelson et al. (113) VASP 125 ACSþPCI >3 days after PCI Serious bleeding 0.97
Rahe-Meyer at al. (55) MEA:ADP 60 Cardiac surgery In-hospital Blood transfusion
Sibbing et al. (39,40) MEA:ADP 2,533 PCI In-hospital TIMI major bleeding 3.50
Ranucci et al. (56) MEA:ADP 87 Thienopyridine treatment In-hospital Post-operative bleeding
PEGASUS-PCI (38) MEA:ADPþPGE1 416 PCI 1 year TIMI major bleeding NS
Campo et al (61) VerifyNow 300 PCI 1 year TIMI major bleeding 0.94
CABG ¼ coronary artery bypass grafting; TIMI ¼ Thrombolysis In Myocardial Infarction; other abbreviations as in Tables 1 and 2.
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1119the cone and platelet analyzer lacks the sensitivity to
predict ischemic events in clopidogrel-treated patients
(AUC: 0.53 to 0.62).
Plateletworks. The Plateletworks test (Helena Laboratories,
Beaumont, Texas) is based on single platelet disappearance.
Whole-blood samples are collected in tubes containing
Ethylenediaminetetraacetic acid (EDTA) and tubes con-
taining ADP. Single platelet counts are performed on each
sample. The ratio between the aggregated platelets in the
agonist sample and the platelet count in the reference tube is
used as the degree of platelet aggregation (34).
Advantages of Plateletworks are the small sample volume
and fast results. The disadvantage is lack of standardization.
One study investigated the predictive value of Platelet-
works for ischemic events. In the POPULAR (Do Platelet
Function Assays Predict Clinical Outcomes in Clopidogrel-
Pretreated Patients Undergoing) Elective PCI study, Pla-
teletworks predicted the composite of major ischemic events
with a sensitivity of 63%, speciﬁcity of 59%, and an AUC
of 0.61 (34).
Thrombelastography. The thrombelastography (TEG)
hemostasis analyzer (Haemoscope, Niles, Illinois) measures
platelet–ﬁbrin clot strength. The thrombin assay in its
primary function is insensitive to P2Y12 inhibition and
aspirin effect. Therefore, several protocols for measurement
of the ADP-induced platelet activation (e.g., a platelet
mapping assay) have been developed (48,50,53,83). Most of
the studies used reptilase and factor XIIIa to generate a
cross-linked ﬁbrin clot. The contribution of P2Y12 receptor
to the clot formation is measured by the addition ADP. The
advantage with TEG is the fact that the test assesses several
aspects of thrombus formation and the interaction between
platelets and coagulation system. The disadvantage of the
modiﬁed TEG is a low standardization.
The data showing the usefulness of TEG for prediction of
events are limited to 1 study showing a positive predictive
value for ischemic events of 67% and an AUC of 0.88 (50).
The proposed cutoff is 70% (50).Genotyping: Genes Associated With
the Response Variability to Clopidogrel
Multiple candidate genes involved in clopidogrel absorption,
activation, and inhibition of the P2Y12 receptor have been
shown to correspond with either high or low platelet reactivity.
In line with those associations, different gene variants have
been linked to ischemic or bleeding outcomes (Tables 4 and 5).
CYP2C19. CYP2C19 plays an important role in the metab-
olism of clopidogrel because it is involved in both oxidative
steps. CYP2C19*2 (loss-of-function allele) is frequent, with
approximately 15% of Caucasians and up to 30% Asian
being carriers of at least 1 of these alleles. Because CYP is
highly polymorphic, a growing body of evidence suggests
a possible role for genotyping, especially of the CYP2C19
polymorphism, as a strategy to identify patients who might
not properly beneﬁt from clopidogrel therapy (84–88).
Platelet function studies have shown a gene–dose effect
for this allelic variant: ADP-induced platelet aggregation
increases from wild-type homozygous patients (*1/*1)
through heterozygous (*1/*2) and over to homozygous
(*2/*2) allele carriers (89). In several studies, carriage of the
CYP2C19*2 allele has been shown to be associated with
a reduced antiplatelet effect of clopidogrel and increased risk
for adverse cardiovascular events (10,84,85,90–92). By
contrast, other studies have shown that the effect of clopi-
dogrel was similar in patients who were heterozygous or
homozygous for loss-of-function alleles and in those who
were not carriers of the alleles (38,93,94) (Table 4). The
conﬂicting evidence might be due to the fact that the
CYP2C19*2 allele carriage accounts for only 5% to 12% of
the variation of ADP-induced aggregation (14,84), thus
suggesting that other variables, such as unknown genetic
variants or clinical characteristics, contribute to this
phenomenon.
Other CYP2C19 variants (*3 to *8) have also been iden-
tiﬁed. However, the low allele frequency (<1%) underlies
their minor impact on HTPR (21,95,96) (Table 4).
Table 4. Studies Investigating the Association Between the Genotype and Ischemic Events
Study (Ref. #) Polymorphism N Population Follow-Up Outcome OR/HR
AFIJI (90) 2C19*2 371 MI (at <45 years of age) 6 years MACE 2.26
TRITON TIMI-38 (92) 2C19*2 1,477 PCIþACS 15 months MACE 1.53
Oh et al. (168) 2C19*2 2,146 PCIþDES 1 year MACE 2.62
Shuldiner et al. (84) 2C19*2 227 Elective PCI 1 year MACE 2.42
RECLOSE (91) 2C19*2 772 PCI 6 months ST 3.43
Harmsze et al. (21) 2C19*2 176/420 PCI (ST case/control) 1 year ST 1.7
Sibbing et al. (169) 2C19*2 2,485 PCI 30 days ST 3.81
ONASSIST (10) 2C19*2 123/246 PCI (ST case/control) ST 1.99
Harmsze et al. (15) 2C19*2 725 Elective PCI 1 year MACE NS
Campo et al. (61) 2C19*2 300 PCI 1 year MACE NS
CHARISMA (94) 2C19*2 4,819 CAD or at high risk 2 years MACE NS
Tiroch et al. (170) 2C19*2 928 MI 1 year MACE NS
Sawada et al. (171) 2C19*2 100 PCIþDES 8 months MACE NS
PEGASUS-PCI (38) 2C19*2 416 PCI 1 year ST NS
Jeong et al. (96) 2C19*2 and *3 266 MI 1 year MACE 2.81
FAST-MI (95) 2C19*2, *3,*4,*5 2,208 PCIþMI 1 year MACE 1.98
CURE and ACTIVE (99) 2C19*2 or *3 5,059 ACS or AF 1 year MACE NS
PLATO (93) 2C19*2–*8 10,285 ACS 30 days MACE 1.37
Harmsze et at. (21) 2C9*3 176/420 PCI (ST case/control) 1 year ST 2.4
ONASSIST (10) 2C9*3 123/246 PCI (ST case/control) ST NS
Harmsze et at. (21) CYP3A5*3 176/420 PCI (ST case/control) ST NS
FAST-MI (95) CYP3A5*3 2,208 PCIþMI 1 year MACE NS
Campo et al. (61) CYP3A5*3 300 PCI 1 year MACE NS
ONASSIST (10) CYP3A5*3 123/246 PCI (ST case/control) ST NS
Bouman et al. (101) PON-1 1,982 ACS 1 year ST 12.80
EXCELSIOR (104) PON-1 760 Elective PCI 1 year MACE NS
Campo et al. (107) PON-1 300 PCI 1 month MACE NS
Simon et al. (105) PON-1 2,210 MI 1 year MACE NS
AFIJI (90) PON-1 371 MI (at <45 years of age) 6 years MACE NS
TRITON TIMI-38 (100) ABCB1 2,932 ACSþPCI 15 months MACE 1.72
FAST-MI (95) ABCB1 2,208 PCIþMI 1 year MACE 1.72
ONASSIST (10) ABCB1 123/246 PCI (ST case/control) ST 2.16
Campo et al. (107) ABCB1 300 PCI 1 year MACE NS
PLATO (93) ABCB1 10,285 ACS 1 year MACE NS
Harmsze et at. (21) ABCB1 176/420 PCI (ST case/control) 1 year ST NS
Jeong et al. (96) ABCB1 266 MI 1 year MACE NS
Tiroch et al. (170) ABCB1 928 MI 12 months MACE NS
ONASSIST (10) ITGB3 123/246 PCI (ST case/control) ST 0.52
FAST-MI (95) ITGB3 2,208 PCIþMI 1 year MACE NS
FAST-MI (95) P2Y12 2,208 PCIþMI 1 year MACE NS
ONASSIST (10) P2Y12 123/246 PCI (ST case/control) ST NS
AF ¼ atrial ﬁbrillation; DM ¼ diabetes mellitus; PON-1 ¼ paraoxonase 1; other abbreviations as in Tables 1 and 2.
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1120The gain-of-function mutation (CYP2C19*17) is res-
ponsible for the increased enzyme activity and higher tran-
scription rates of the gene, which result in exaggerated
bioactivation of clopidogrel. The clinical impact of this poly-
morphism regarding bleeding risk is conﬂicting. Although
some studies showed an association of the CYP2C19*17
allele with low platelet reactivity and hemorrhagic events
(61,97,98), other studies did not (38,93,94,96,99) (Table 5).Other candidate genes: ABCB1, PON-1, ITGB3, P2Y12. Several
other gene candidates have been proposed as independent
predictors of clopidogrel response and adverse clinical
outcomes (Table 4). As with the CYP2C19 gene, available
data are also conﬂicting for the clinical impact of poly-
morphisms of genes involved in clopidogrel intestinal
efﬂux (ABCB1), activation (paraoxonase-1, PON-1),
intracellular signaling (ITGB3 encoding the integrin b3 of
Table 5. Studies Investigating the Association Between the Genotype and Bleeding Events
Study (Ref. #) Polymorphism N Population Follow-Up Outcome OR/HR
Sibbing et al. (98) 2C19*17 1,524 PCI 30 days TIMI major bleeding 1.8
Campo et al. (61) 2C19*17 300 PCI 1 year TIMI major bleeding 2.3
Harmsze et al. (172) 2C19*17 820 Elective PCI 1 year TIMI major bleeding 2.7
Jeong et al. (96) 2C19*17 266 MI 1 year TIMI major bleeding NS
CURE and ACTIVE (99) 2C19*17 5,059 ACS or AF 1 year Major bleeding NS
CHARISMA (94) 2C19*17 4,819 CAD or at high risk 2 years GUSTO severe bleeding NS
PEGASUS-PCI (38) 2C19*17 416 PCI 1 year TIMI major bleeding NS
GUSTO ¼ Global Use of Strategies to Open Occluded Coronary Arteries; other abbreviations as in Tables 1, 2, and 3.
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1121the GP-IIb/IIIa receptor), or binding site for its active
metabolite (gene encoding the P2Y12 receptor). Some
studies have shown that these polymorphisms corresponded
to higher rates of cardiac ischemic events (10,95,100–102).
However, numerous independent studies have not
conﬁrmed these observations (10,90,93,95,103–107).
Therefore, further studies are required to conﬁrm or refute
an impact of these genes on the antiplatelet effect of
clopidogrel.
Assays for Bedside Genotyping
For research purposes, conventional laboratory-based
methods such as TaqMan (Life Technologies, Carlsbad,
California) genotyping or DNA sequencing are widely used.
Because these techniques are time-consuming, genotyping
in clinical routine can only be adopted with the use of point-
of-care assays. Two assays for CYP2C19*2 that fulﬁll
the point-of-care requirements are available at present: the
Spartan RX system (Spartan Bioscience, Ottawa, Ontario,
Canada) and the Verigene XP system (Nanosphere,
Northbrook, Illinois). There are several differences between
the systems. The Verigene system uses whole blood, the
Spartan system uses a buccal swab. The Verigene system
detects the polymorphisms based on gold nanoparticle
techniques, whereas the Spartan system uses polymerase
chain reaction. The Verigene system allows the genotyping
of several CYP2C19 allelic variants, whereas the Spartan
system detects only CYP2C19*2. The time to get results is
shorter for the Spartan system compared with the Verigene
system: 1 versus 3 h. Several further assays are currently
under development.
Potent P2Y12 Inhibitors
Response variability to clopidogrel has led to the develop-
ment of more potent P2Y12 inhibitors such as prasugrel and
ticagrelor. The pharmacokinetics and pharmacodynamics of
prasugrel and ticagrelor indicate that they provide more
consistent, more rapid, and more potent platelet inhibition
than clopidogrel, which has been shown to translate intoimproved clinical outcomes. On the other hand, enhanced
efﬁcacy of these antiplatelet drugs is associated with an
increased risk of spontaneous major bleeding (4).
Prasugrel is an oral third-generation thienopyridine that
acts as an irreversible oral inhibitor of the P2Y12 receptor.
Prasugrel, similar to clopidogrel, requires hepatic bio-
activation (Fig. 2). Prasugrel undergoes rapid deacetylation
by intestinal esterases with the formation of an inactive
thiolactone metabolite. Although the active metabolite is
formed from the thiolactone by oxidative metabolism
via various CYP isoenzymes (CYP3A4/5, CYP2B6,
CYP2C19, CYP2C9) (108), the common functional CYP
genetic variants do not affect formation of the active
metabolite, inhibition of platelet aggregation, or the clinical
outcome of prasugrel-treated patients (109). In the
TRITON-TIMI 38 (Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet Inhibition
with Prasugrel–Thrombolysis in Myocardial Infarction 38)
trial, prasugrel reduced ischemic events by 19% compared
with clopidogrel (110).
Ticagrelor, a cyclopentyl-triazolo-pyrimidine, is an oral
antagonist of the P2Y12 receptor that inhibits platelets in
a reversible manner. Ticagrelor does not require hepatic
bioactivation because it is an active drug. However, the
major metabolite of ticagrelor (AR-C124910XX) formed by
metabolism via CYP3A4 also has antiplatelet properties
(Fig. 2) (111). In contrast to clopidogrel and prasugrel,
which prevent ADP binding to the P2Y12 receptor and
cause extracellular structural change, ticagrelor acts via an
allosteric modulation site: it binds to the receptor indepen-
dently from ADP and inhibits its conformational change
(Fig. 3). The PLATO (Platelet Inhibition and Patient
Outcomes) trial has shown that ticagrelor reduced ischemic
events by 16% and cardiovascular mortality by 21% as
compared with clopidogrel (112). Potential disadvantages of
ticagrelor include side effects such as dyspnea, ventricular
pauses, and increased concentrations of uric acid and
creatinine.
Although it has been assumed that the use of novel
P2Y12 receptor antagonists would overcome the problem of
HTPR, real-world data show that HTPR is observed in
Figure 3. Binding Sites of Platelet Inhibitors at the P2Y12 Receptor
Gi ¼ inhibitory G protein; other abbreviations as in Figure 1.
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1122certain clinical settings with prasugrel and ticagrelor also,
which correlated with higher rates of ischemic events
(47,113–115). In line with these results, trials in chronic
hemodialysis patients who were clopidogrel nonresponders
indicated that 12% to 19% of them were also prasugrel
nonresponders (116,117). In ST-segment elevation myo-
cardial infarction (STEMI) patients randomized to tica-
grelor or prasugrel, both agents exhibited similar platelet
inhibition over time, with 46.2% nonresponders for tica-
grelor and 34.6% for prasugrel 2 h after the respective
loading doses (115). Accordingly, neither prasugrel nor
ticagrelor showed a consistent effect in reducing platelet
function during or shortly after primary percutaneous coro-
nary intervention (PCI) in STEMI patients (115).
Tailored Antiplatelet Treatment
Several studies have demonstrated that the level of clopi-
dogrel-induced platelet inhibition can be improved with
higher loading or maintenance doses of clopidogrel, by
adding elinogrel, cilostazol, or a GP-IIb/IIIa antagonist, orby switching to prasugrel or ticagrelor (118–122). With
regard to genotype-based personalized treatment, even
900-mg loading doses of clopidogrel did not overcome
HTPR to clopidogrel in homozygous CYP2C19*2 allele
carriers (123). Interestingly, in the ACCELAMI2C19
(Adjunctive Cilostazol Versus High Maintenance-Dose
Clopidogrel in Acute Myocardial Infarction [AMI] Patients
According to CYP2C19 Polymorphism) study, adjunctive
cilostazol compared with high-maintenance-dose clopidogrel
reduced the rate of HTPR in patients with CYP2C19 loss-of-
function variants presenting with an acute myocardial
infarction (124). Several other studies evaluating the asso-
ciation between genetic proﬁling and platelet response to
clopidogrel were terminated (PAPI-2 [Proﬁle The Amish
Pharmacogenomics of Anti-Platelet Intervention], GeCCO
[Genotype Guided Comparison of Clopidogrel and Prasu-
grel Outcomes Study]), whereas other studies are still
recruiting patients (DANTE [Dual Antiplatelet Therapy
Tailored on the Extent of Platelet Inhibition], GIANT
[Genotyping Infarct Patients to Adjust and Normalize
Thienopyridine Treatment]). In smaller studies, guided
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1123therapy with up to 4 clopidogrel reloadings or addition of
GP-IIb/IIIa antagonists in patients initially nonresponding
to clopidogrel resulted in a reduction of MACE (67,125–128).
Several randomized clinical trials (ARCTIC [Double
Randomization of a Monitoring Adjusted Antiplatelet
Treatment Versus a Common Antiplatelet Treatment for
DES Implantation, and Interruption Versus Continuation
of Double Antiplatelet Therapy], N ¼ 2,440; GRAVITAS
[Gauging Responsiveness With A VerifyNow Assay-Impact
On Thrombosis And Safety], N ¼ 2,200; and TRIGGER-
PCI [Testing Platelet Reactivity In Patients Undergoing
Elective Stent Placement on Clopidogrel to Guide Alter-
native Therapy With Prasugrel], N ¼ 423) have investi-
gated whether clinical outcome can be improved using
individualized antiplatelet strategy. In the ARCTIC trial,
poor responders received either an additional loading dose
plus an increased maintenance dose of clopidogrel (600 mg/
150 mg), a switch to prasugrel, an increase of the aspirin
dose, or additional treatment with GP-IIb/IIIa inhibitors
(129). In the GRAVITAS trial, clopidogrel nonresponders
received an additional loading dose plus an increased
maintenance dose of clopidogrel (600 mg/150 mg) (58).
The TRIGGER-PCI trial compared prasugrel versus clo-
pidogrel in patients with HTPR to clopidogrel (60).
However, guided antiplatelet therapy did not improve
patients’ outcomes in the GRAVITAS or ARCTIC trials
(58,129). The TRIGGER-PCI trial was stopped prema-
turely for futility because an interim analysis indicated
a lower-than-expected incidence of the primary endpoint
(60). Despite reducing platelet reactivity, a strategy of
personalized antiplatelet therapy did not reduce the inci-
dence of ischemic events in GRAVITAS or ARCTIC.
There are several critical issues regarding the design of these
trials that might have led to the negative study results. The
primary endpoint in the ARTIC trial was mainly based on
the incidence of periprocedural myocardial infarction, which
is unlikely to be prevented by use of intensiﬁed platelet
inhibition (130). The inclusion of elevated troponins into
the deﬁnition of myocardial infarction in the ARCTIC trial
explains the difference in the incidence of myocardial
infarction between the ARCTIC (30.2%), GRAVITAS
(1.8%), and TRIGGER-PCI (0%) trials (58,60,129).
Accordingly, patients with ST-segment elevation myocar-
dial infarction were excluded, and patients with non–ST-
segment elevation acute coronary syndromes represented
only 25% of the ARCTIC population; and high-risk
patients were excluded from the GRAVITAS and the
TRIGGER-PCI trials. Furthermore, because randomiza-
tion was performed late in these trials (12 to 24 h after PCI
in the GRAVITAS trial, and 2 to 7 h after the ﬁrst clo-
pidogrel maintenance dose intake the day after successful
PCI in the TRIGGER-PCI trial), patients experiencing
periprocedural events were not included. Moreover, inad-
equate personalized therapy might be responsible for theresults: in the ARCTIC trial, only 3.3% of patients were
switched to prasugrel; in the GRAVITAS trial, 40% of
patients in the guided group remained nonresponders after
the switch to a high dose of clopidogrel. Finally, the
studies might have been underpowered.
In contrast to the results of these single studies, a meta-
analysis of 10 randomized trials showed that intensiﬁed
antiplatelet treatment was associated with a signiﬁcant
reduction in cardiovascular mortality, stent thrombosis, and
myocardial infarction (131). Interestingly, meta-regression
analysis revealed that the net clinical beneﬁt of the intensi-
ﬁed treatment signiﬁcantly depended on the baseline risk for
stent thrombosis.Conclusions
Clinical outcomes and treatment options in patients
undergoing elective PCI have improved. Nevertheless,
considering that there might be a therapeutic window for
P2Y12 inhibitors, there still might be room for optimiza-
tion of antiplatelet therapy. Furthermore, because negative
trials on the use of personalized antiplatelet therapy have
been criticized for inappropriate study design, patient
populations that might beneﬁt from the use of proper
protocols of tailored antiplatelet treatment remain to be
characterized.
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